15:19:43 EST Tue 17 Nov 2026
Enter Symbol
or Name
USA
CA



Medmira Inc
Symbol MIR
Shares Issued 758,307,062
Close 2026-11-16 C$ 0.05
Market Cap C$ 37,915,353
Recent Sedar+ Documents

Medmira receives breakthrough designation for Multiplo

2026-11-17 15:08 ET - News Release

Mr. Hermes Chan reports

MEDMIRA RECEIVES U.S. FDA BREAKTHROUGH DEVICE DESIGNATION FOR ITS MULTIPLO COMPLETE SYPHILIS (TP/NTP) ANTIBODY TEST

The United States Food and Drug Administration (FDA) has granted breakthrough device designation to Medmira Inc.'s Multiplo Complete Syphilis (TP/nTP) Antibody Test.

The designation, granted through the FDA's Center for Devices and Radiological Health (CDRH), recognizes the device's potential to provide a more effective diagnostic approach for syphilis, a serious infectious disease that continues to present significant public health challenges in the United States and around the world.

The Multiplo Complete Syphilis (TP/nTP) Antibody Test utilizes Medmira's proprietary rapid vertical flow (RVF) technology to simultaneously detect treponemal (TP) and non-treponemal (nTP) antibodies from a single fingerstick whole-blood specimen. Unlike conventional laboratory-based testing approaches that may require separate testing procedures, the device provides both antibody results in a rapid, visually interpreted format without the need for specialized instrumentation.

A significant milestone for Medmira

"This is an extraordinary milestone for Medmira and a tremendous recognition of the dedication, perseverance and scientific innovation of our entire team," said Hermes Chan, chief executive officer of Medmira. "The FDA's decision reinforces the potential significance of our technology and represents an important step as we advance our development program toward the U.S. market."

"We are also particularly encouraged that, following the breakthrough device designation, FDA's Total Product Life Cycle Advisory Program (TAP) team has invited Medmira to apply for enrollment in its TAP pilot. We welcome this opportunity to pursue closer collaboration with FDA as we advance our U.S. clinical and regulatory development strategy.

"For many years, we have believed that meaningful innovation in diagnostics should not only advance scientific capabilities but also make essential health care more accessible to the people who need it most. For me, this achievement represents much more than a regulatory milestone. It reflects our long-standing belief that the real purpose of innovation is using science to improve people's lives."

Addressing an important public health need

Syphilis continues to pose significant challenges to health care systems, with delayed diagnosis and treatment contributing to continuing transmission and potentially serious complications, including congenital syphilis.

Conventional syphilis diagnosis typically relies on both treponemal and non-treponemal testing, which may require laboratory infrastructure, multiple procedures and additional patient follow-up.

Medmira's Multiplo Complete Syphilis (TP/nTP) Antibody Test is designed to combine these two complementary antibody measurements into a single point-of-care procedure, potentially enabling health care professionals to obtain clinically relevant information more quickly.

The technology may be particularly valuable in community health centres, outreach programs, remote communities and other health care settings where immediate access to conventional laboratory services is limited.

FDA Breakthrough Devices Program

The FDA's Breakthrough Devices Program is intended to facilitate the development and review of certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.

Devices granted breakthrough device designation may benefit from prioritized interaction with the FDA and opportunities for more frequent communication regarding development plans, clinical study design and regulatory requirements.

The designation does not constitute FDA clearance or approval for commercial marketing in the United States, nor does it eliminate applicable regulatory requirements.

About Medmira Inc.

Medmira is a leading developer and manufacturer of rapid vertical flow diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as HIV, syphilis, hepatitis and SARS-CoV-2, in just three easy steps. The company's tests are sold globally under the Reveal, RevealCOVID-19, Multiplo and Miriad brands. Based on its patented rapid vertical flow technology, Medmira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. Medmira's corporate offices and manufacturing facilities are located in Halifax, N.S., Canada.

We seek Safe Harbor.

© 2026 Canjex Publishing Ltd. All rights reserved.